CJ Bioscience
CJ Bioscience develops microbiome drugs CJRB-101, CJRB-201 via AI platform Ez-Mx®, and runs gut-health services GUT INSIDE, SMILE GUT.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2009 and listed on KOSDAQ in 2019, CJ Bioscience is a microbiome-focused bioscience company. Using its AI-based microbiome analysis platform Ez-Mx®, it is developing CJRB-101 for lung and head-and-neck cancer in combination with Keytruda, and CJRB-201 for inflammatory bowel disease, alongside an EzBioCloud-based NGS/BI solution and gut-health services GUT INSIDE and SMILE GUT. The company has built a Gut Microbiome Index (GMI) based on more than 140,000 microbiome data points.
Products & technology
- Ez-Mx®AI-based microbiome drug discovery platform
- EzBioCloudMicrobial genome NGS/BI integrated analysis solution
- GUT INSIDEGut microbiome health analysis service for medical institutions
- SMILE GUTConsumer-facing gut health diagnostic service
Regulatory approvals
data.go.kr3 Korean MFDS device approvals · 2018–2025
- MFDSSpecimen transport media2025-10-01Product approval · Class 1체외 제신 25-1320 호
- MFDSSpecimen transport media2019-05-07Product approval · Class 1체외 제신 19-571 호
- MFDSOther reagent of sample preparation kit2018-09-21Product approval · Class 1체외 제신 18-1279 호
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 1/2 1)
- Phase 1/2CJRB-1012023-06-15
6 trial sites
R&D and key agreements
Source: DART corporate disclosureCJRB-101 · 폐암, 두경부암 · 임상(키트루다 병용요법, 미국·한국 동시 진행) · Microbiome combination candidate identified via Ez-Mx® platform, combined with Keytruda
CJRB-201 · 염증성 장질환(IBD) · 전임상(동물실험 완료, 임상 진입 목표) · Demonstrated antibody-level anti-inflammatory effect in animal studies
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer1
- OpenAIOAI-SearchBot1
Measured since Aug 25, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).
Synergy Innovation, founded in 1998 and KOSDAQ-listed in 2004, manufactures and sells microbial culture media.
Founded in 2006 and KOSDAQ-listed in 2017, ASTA develops MALDI-TOF mass spectrometry diagnostic and industrial systems.
KOSDAQ-listed ADC oncology biotech that has out-licensed pipeline candidates to Biohaven, SK Plasma, and Boehringer Ingelheim.
Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
Founded in 1999 and KOSDAQ-listed in 2021, BIODYNE develops liquid-based cytology (LBC) devices and diagnostic reagent kits.
Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition